We were advised in NEU’s Q2 2024 update last week that Acadia’s Paediatric Investigation Plan for trofinetide in Rett syndrome had been agreed to by the EMA. For a new paediatric drug, a PIP has to be submitted to and agreed to by the EMA before you can submit an MMA for marketing approval can be submitted. The PIP procedure is said to typically take 9-12 months. That bit is now done.
It was also advised that Acadia intends to submit the MMA for European marketing approval for DayBue in Q 1 next year. Assuming the Accelerated Assessment pathway is taken, it might take ~12 months for approval. If things run smoothly,DayBue might on the market in Europe by Q2 2026.
Reata submitted its MMA for SkyClarys in November or December 2022, received recommendation for approval in December 2023 and formal marketing approval in February 2024.
- Forums
- ASX - By Stock
- NEU
- NEU is materially undervalued
NEU is materially undervalued, page-51
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$13.11 |
Change
0.410(3.23%) |
Mkt cap ! $1.675B |
Open | High | Low | Value | Volume |
$13.02 | $13.12 | $12.89 | $8.524M | 654.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 5580 | $13.04 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.11 | 11667 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 5580 | 13.040 |
1 | 1637 | 13.020 |
4 | 15028 | 13.000 |
1 | 39 | 12.990 |
1 | 2028 | 12.980 |
Price($) | Vol. | No. |
---|---|---|
13.120 | 3413 | 2 |
13.140 | 2028 | 1 |
13.150 | 139 | 3 |
13.160 | 2028 | 1 |
13.180 | 2028 | 1 |
Last trade - 16.10pm 17/10/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non Executive Director
Simon Kidston
Non Executive Director
SPONSORED BY The Market Online